Federal grant · project grant (b)
Remmie.ai a Deep Learning Diagnostic Engine for Ear-nose Throat Disease - Project Summary Otitis Media (om), Commonly Referred to as an Ear Infection, Is the Most Common Reason for Antibiotics Use in Children Under 6 Years of Age. Om Is Also the Second-most Common Cause of Hearing Loss Globally, Impacting 1.4 Billion Individuals in 2017 and Currently Ranked as the Fifth Highest Disease Burden. Otitis Media With Effusion (OME) Is a Condition Characterized by the Presence of Fluid Behind the Eardrum, Often Causing Hearing Difficulties, While Acute Otitis Media (AOM) Refers to a Sudden and Painful Infection of the Middle Ear, Commonly Associated With Fever and Earache. Perforated Eardrum and Tympanosclerosis Can Result From Untreated Om, and These Conditions Can Lead to Hearing Loss and Other Complications When Left Untreated. to Prevent Unnecessary and Harmful Delays to Om Diagnosis and Management, There Is a Significant Need for Widespread, Affordable, and Convenient Access to Otolaryngology Specialists. Om Is an Ideal Candidate for Real-time Telemedicine Visits Due to Its Defined Symptoms and Visual Diagnosis That Can Be Accomplished With Straightforward Data Points and Imaging. However, No Platform Currently Exists to Facilitate Effective Virtual Visits for Ear Infections. the Overall Goal of This Phase Ii Project Is to Further Develop and Validate Remmie.ai, a Next- Generation Ear-nose-throat (ENT) Mobile Health Platform, as an Innovative Telemedicine Solution for Accurate and Efficient Diagnosis of Om. the Three Aims Outlined in This Proposal Converge to Empower Remmie.ai as a Transformative Force in Healthcare. Aim 1 Leverages Extensive Image and Data Collection Efforts to Further Refine Remmie.ai Models, Enabling Precise Classification of Om. Aim 2 Orchestrates Real-world Clinical Testing to Validate Remmie.ai's Effectiveness, Assessing Its Impact on Diagnoses and Patient Care in Both In-person and Telemedicine Settings. Finally, Aim 3 Charts a Path Towards Fda Designation by Fortifying the Platform's Infrastructure for Data Privacy and Security, Ensuring Regulatory Compliance, and Refining the User-friendly Remmie App. Together, These Aims Harmonize Data-driven Ai Enhancements, Clinical Validation, and Regulatory Groundwork, Propelling Remmie.ai Towards Its Overarching Goal of Democratizing Access to Otolaryngology Expertise and Improving the Diagnosis and Management of Ent Conditions While Safeguarding Patient Privacy and Adhering to Regulatory Standards.
Committed
$3.0 Million
Paid out
$2.8M
95%
Committed, not yet paid
$150.0K
5%
Loading…
Everything here is this single award's whole record — signed, amended, paid — not a fiscal-year slice. The by-year charts elsewhere split an award across the years it was committed; this page keeps it whole.
Committed is what the government has legally promised on this award so far. Contracts can also carry a ceiling — the maximum if every option is exercised. Unspent ceiling is headroom, not money owed.
The cash actually disbursed against this award. The gap from committed is the disbursement pipeline: promised, not yet cashed.
Each transaction is a signing event — an action that created or changed the award, dated the day it was signed — not a payment. Negative amounts are real: money de-committed at closeout or renegotiation.
One bar, the award’s whole arithmetic: paid out, then committed, not yet paid, then unspent ceiling.